Identification of BRCA1-deficient ovarian cancers

Acta Obstetricia et Gynecologica Scandinavica

Volumn 90, Issue 6, 2011, Pages 593-599

  Skytte, Anne Bine ^a   Waldstrøm, Marianne ^b   Rasmussen, Anders Aamann ^a   Crüger, Dorthe ^a   Woodward, Emma R ^c,d   Kølvraa, Steen ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

BRCA1; BRCA1 fluorescence in situ hybridization; BRCA1 immunohistochemistry; methylation; ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC ANALYSIS; GERM LINE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

BRCA1 PROTEIN; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 79956201393     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2011.01121.x     Document Type: Article

References (28)

1. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al,. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361: 123-34.
2. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al,. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000; 283: 2260-5. (Pubitemid 30246777)
3. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al,. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104: 2807-16. (Pubitemid 41798292)
4. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al,. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68: 700-10. (Pubitemid 32203724)
5. Deng CX,. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006; 34: 1416-26.
6. Kato H, Arakawa A, Suzumori K, Kataoka N, Young SR,. FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples. Exp Mol Pathol. 2004; 76: 138-42. (Pubitemid 38324592)
7. Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, et al,. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol. 2004; 202: 215-23. (Pubitemid 38208659)
8. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al,. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008; 8: 17.
9. Easton DF, Bishop DT, Ford D, Crockford GP,. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993; 52: 678-701. (Pubitemid 23310135)
10. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al,. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-30. (Pubitemid 36530000)
11. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA,. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2006; 16 (Suppl 1): 166-71.
12. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al,. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005; 33: 6823-36. (Pubitemid 41830488)
13. Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, et al,. Methylated DNA collected by tampons-a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13: 882-8. (Pubitemid 38737880)
14. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al,. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38: 787-93. (Pubitemid 43980599)
15. Al-Mulla F, Abdulrahman M, Varadharaj G, Akhter N, Anim JT,. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem. 2005; 53: 621-9. (Pubitemid 40593975)
16. Sogaard M, Kjaer SK, Gayther S,. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand. 2006; 85: 93-105. (Pubitemid 43879130)
17. Catteau A, Morris JR,. BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol. 2002; 12: 359-71.
18. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, et al,. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 2009; 8: 48.
19. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al,. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001; 10: 3001-7. (Pubitemid 34083486)
20. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE,. Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer. 2009; 8: 339-46.
21. Staff S, Nupponen NN, Borg A, Isola JJ, Tanner MM,. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. Genes Chromosomes Cancer. 2000; 28: 432-42. (Pubitemid 30451796)
22. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE,. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006; 8: R38.
23. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al,. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004; 10: 2473-81. (Pubitemid 38445709)
24. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA,. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 1999; 59: 868-71.
25. Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH, et al,. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 2002; 21: 407-11.
26. Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, et al,. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol. 2004; 23: 29-34. (Pubitemid 38018234)
27. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL,. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005; 91: 179-86. (Pubitemid 40684930)
28. Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS, et al,. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol. 2008; 47: 772-7. (Pubitemid 351878455)